Cannabis Bioavailability: Why Edibles, Vapes, and Tinctures Hit Differently

What Bioavailability Means

Bioavailability is the fraction of an administered dose that reaches systemic circulation in active form. A 100% bioavailable drug would mean that every molecule in the dose arrives in your bloodstream unchanged. That standard only applies to intravenous injection. Every other delivery route involves absorption barriers, enzymatic breakdown, and metabolic processing that reduces the fraction of the original dose that reaches its target.

For cannabis specifically, bioavailability matters for two distinct reasons. First, it determines the effective dose at the receptor level (how much THC or CBD actually reaches the endocannabinoid system). Second, it determines which metabolites are formed along the way. Oral cannabis produces different metabolites than inhaled cannabis, not just different quantities of the same metabolites. The route of administration changes the biochemistry of the experience, not just the intensity.

Bioavailability by Delivery Method

The wide range within each category reflects genuine individual variation. Body fat percentage, liver enzyme activity, gut microbiome composition, and fed versus fasted state all shift where someone lands within those ranges. The numbers in the table are population averages from pharmacokinetic research, not precise predictions for any individual dose.

Inhalation: Fastest Path, Variable Efficiency

Inhaled cannabis delivers THC directly to the alveoli in the lungs, where the surface area available for absorption is roughly the size of a tennis court packed into your chest. THC crosses the alveolar membrane into the pulmonary circulation and reaches the brain within seconds to minutes, bypassing the digestive system and liver entirely on the first pass. No other common delivery method produces faster onset.

The 25 to 35% bioavailability figure is a population average that conceals wide individual variation in technique. How deeply you inhale, how long you hold the vapor, and whether you exhale quickly or let the lungs absorb completely shift effective delivery significantly. Studies measuring blood THC concentrations after inhalation show two- to three-fold differences between subjects consuming identical amounts (a spread that reflects technique variation more than individual pharmacology).

Vaping and smoking both deliver THC through inhalation, but at different temperatures and with different compound profiles reaching the lungs. Vaporization at controlled temperatures preserves terpenes and produces a cleaner cannabinoid profile. Combustion produces pyrolytic byproducts (including some that are carcinogenic) alongside the cannabinoids. Bioavailability between the two methods is roughly comparable at appropriate temperatures, but the compound profile and lung exposure differ meaningfully.

Oral / Edibles: Low Bioavailability, High Conversion

Swallowing THC sends it on the longest, most metabolically eventful route of any delivery method. From the GI tract, absorbed THC travels through the portal vein to the liver before reaching systemic circulation. The liver’s first-pass metabolism converts a large fraction of that THC into 11-OH-THC (11-hydroxy-THC) before it ever reaches the brain. What’s left of the original THC then enters the bloodstream alongside the 11-OH-THC it produced.

11-OH-THC crosses the blood-brain barrier more readily than THC itself, binds CB1 receptors with similar affinity, and clears more slowly than THC. The edible experience (longer, heavier, more physically sedating, harder to titrate) is largely a function of this metabolite profile rather than the THC that survived the first pass. When people say edibles hit different, the pharmacology agrees. They’re right for reasons they probably don’t know.

The 4 to 12% bioavailability range for edibles is also the most variable of any delivery method. Individual differences in gut absorption efficiency, liver enzyme activity (specifically CYP2C9 and CYP3A4, the enzymes that metabolize THC), and the fat content of the meal consumed with the edible produce wildly different effective doses from the same labeled milligrams.

Sublingual: Bypassing the First Pass

Sublingual delivery (holding a tincture, strip, or oil under the tongue rather than swallowing it) absorbs cannabinoids through the mucous membranes of the mouth directly into the bloodstream. The sublingual route has an exceptionally dense capillary network that provides rapid access to systemic circulation without passing through the digestive system or liver first. No first-pass metabolism means THC arrives as THC rather than being partially converted to 11-OH-THC before reaching the brain.

The practical difference between sublingual and oral cannabis is onset and metabolite profile. Hold a tincture under the tongue for 60 to 90 seconds before swallowing: onset in 15 to 45 minutes, peak in one to two hours, duration four to six hours, and the experience resembles inhalation more than it resembles a full edible. Swallow it immediately: onset in 30 to 90 minutes, slower peak, longer duration, and 11-OH-THC dominates the experience. The same tincture. The same dose. Different experience based entirely on where in the mouth the absorption happens.

Most tinctures sold as sublingual products contain oil-based carriers that help cannabinoid absorption through the mucous membranes. Water-soluble or nanoemulsion tinctures are absorbed even more efficiently sublingually because cannabinoids are naturally lipophilic and the aqueous mucous membrane environment is not their ideal medium. Emulsification improves contact and absorption rate for oil-in-water formulations.

Topical: Local Without Systemic

Cannabinoids applied to the skin interact with CB1 and CB2 receptors in the layers of the skin and underlying tissue, but they do not meaningfully reach systemic circulation under normal use conditions. The skin’s outermost layer (the stratum corneum) is an effective barrier against lipophilic compounds like THC and CBD. The localized CB1 and CB2 receptor populations in skin and peripheral sensory neurons respond to topical cannabinoids, but bloodstream concentrations remain negligible.

This matters for two practical reasons. First, topical cannabis products don’t produce psychoactive effects. There’s no meaningful CB1 activation in the brain because the compounds aren’t reaching the brain. Second, topical products carry no drug test risk because they produce no detectable metabolites in urine. The local CB2 anti-inflammatory and peripheral pain-modulating effects are accessible without any systemic pharmacology.

Transdermal products (patches designed to drive cannabinoids through the skin into systemic circulation) operate differently from topicals. Transdermal delivery uses penetration enhancers to actively push cannabinoids past the stratum corneum into the dermis and capillary beds. This can produce detectable blood concentrations and, at sufficient doses, systemic effects including psychoactivity. A transdermal THC patch is not a topical. The two categories share a delivery surface but not a mechanism or a pharmacological outcome.

What Shifts Bioavailability Within Each Method

Body composition

THC is fat-soluble and distributes extensively into adipose tissue. People with higher body fat percentages have a larger reservoir for THC storage, which produces lower peak blood concentrations from the same dose (more is absorbed into fat before reaching the brain) and slower clearance (stored THC releases back into circulation gradually over time).

Liver enzyme genetics

CYP2C9 and CYP3A4 are the primary hepatic enzymes responsible for THC metabolism. Genetic variants in these enzymes produce meaningful differences in how fast individuals process THC. Fast metabolizers reach lower peak THC concentrations and clear the compound more quickly. Slow metabolizers accumulate higher peak concentrations and extend the duration of effects. This genetic variation is one reason identical doses produce dramatically different experiences in different people, and why “start low, go slow” is not just cautious advice but pharmacologically justified guidance.

Tolerance and receptor downregulation

Regular cannabis use produces CB1 receptor downregulation in brain regions most exposed to THC. The receptors don’t disappear but their density and sensitivity decrease. A daily user requires a higher effective dose to achieve the same receptor activation that a first-time or occasional user gets from a smaller amount. Tolerance is not a bioavailability change in the pharmacokinetic sense. The same percentage of THC still reaches the bloodstream. The difference is at the receptor end, where there are fewer receptors available to respond.

Fed versus fasted state

For oral and sublingual delivery, consuming cannabis with food (particularly fatty food) increases absorption significantly. For inhalation, the fed or fasted state has minimal effect on bioavailability. For topicals, dietary state is irrelevant. The fat effect on oral bioavailability is large enough to change the practical dose category: the same gummy consumed after avocado toast and after a 16-hour fast may produce meaningfully different experiences for the same person.

What This Means for Dosing

Dosing advice that works for one delivery method often fails when applied to another. A person who reliably uses 10mg inhaled THC cannot assume that 10mg in an edible will produce a similar experience. The effective dose at the receptor level differs, the metabolite profile differs, and the timeline differs by a factor of two to four hours.

• Inhalation titrates easily. Onset in minutes allows real-time dose adjustment. Take one or two draws, wait ten minutes, assess, and continue if needed. The short duration means dosing errors resolve within two to three hours.
• Edibles require patience. The single most common edible mistake is re-dosing before the first dose has peaked. Full onset on a full stomach can take up to two hours. Re-dosing at 60 minutes produces a stacked dose that arrives simultaneously at peak. Wait the full two hours before concluding the initial dose was insufficient.
• Sublingual tinctures offer middle ground. Faster than edibles, more controlled than inhalation for many users. The sublingual hold time matters: 60 to 90 seconds under the tongue before swallowing maximizes the direct absorption that distinguishes tinctures from edibles.
• Topicals are site-specific. Apply to the target area, allow 15 to 30 minutes for absorption, and assess the local effect. Systemic effects or psychoactivity indicate either a transdermal (not topical) product or an unusual individual absorption event.